Seelos Therapeutics to Participate in Investor Conferences in November
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in two investor conferences in November 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in two investor conferences in November 2020. The events include the Jefferies Virtual Global Healthcare Conference from November 17-19 and the Benchmark Virtual Discovery One on One Investor Conference on November 18. Senior management, including Chairman and CEO Raj Mehra and Head of Research and Development Dr. Tim Whitaker, will host one-on-one meetings via conference calls. Seelos focuses on developing therapies for central nervous system disorders and rare diseases.
Details
News Market Reaction – SEEL
The recorded move for SEEL in the trading session of this news was +2.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Oct. 22, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in two investor conferences in November.
Seelos Therapeutics' senior management will participate in:
- Jefferies Virtual Global Healthcare Conference, Tuesday-Thursday, November 17-19
- Benchmark Virtual Discovery One on One Investor Conference, Wednesday, November 18
Raj Mehra, Ph.D., Chairman and CEO and Dr. Tim Whitaker, MD, Head of Research and Development, will host 1x1 meetings via conference calls.
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-investor-conferences-in-november-301157408.html
SOURCE Seelos Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.